CapsoVision (CV)
Swallowable capsule imaging and video workflows for small-bowel examinations.
$6.30
After hours0.00 (0.00%)
At close$6.30(+1.78%)
In millions of USD, except per-share figures
| In millions | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 3 | 4 |
| Cost of revenue | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 1 | 2 |
| Gross profit | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 |
| 6 | 7 | 7 | 6 | 7 | 6 | 2 | 9 | 8 | 9 | |
| Research & development | 3 | 4 | 5 | 3 | 3 | 3 | 6 | 6 | 4 | 5 |
| 2 | 3 | 3 | 3 | 4 | 3 | 4 | 4 | 4 | 4 | |
| Selling & marketing | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 |
| General & administrative | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 0 | 2 | 2 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | −8 | 0 | 0 | 0 |
| Operating income | −4 | −5 | −6 | −5 | −5 | −5 | 0 | −7 | −7 | −8 |
| 0 | 0 | 0 | 0 | 0 | 0 | −8 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 |
| Income before tax | −4 | −5 | −6 | −5 | −5 | −5 | −8 | −7 | −7 | −7 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −4 | −5 | −6 | −5 | −5 | −5 | −8 | −7 | −7 | −7 |
| Net income | −4 | −5 | −6 | −5 | −5 | −5 | −8 | −7 | −7 | −7 |
| EPS, basic | −$0.10 | −$0.13 | −$0.14 | −$0.10 | −$0.12 | −$0.10 | −$0.17 | −$0.16 | −$0.15 | −$0.15 |
| EPS, diluted | −$0.10 | −$0.13 | −$0.14 | −$0.10 | −$0.12 | −$0.10 | −$0.17 | −$0.16 | −$0.15 | −$0.15 |
| Weighted average shares, basic | 41 | 41 | 41 | 46 | 46 | 46 | 46 | 47 | 47 | 50 |
| Weighted average shares, diluted | 41 | 41 | 41 | 46 | 46 | 46 | 46 | 47 | 47 | 50 |
| EBITDA | −4 | −5 | −6 | −5 | −5 | −5 | −8 | −7 | −7 | −7 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −4 | −5 | −6 | −5 | −5 | −5 | −8 | −7 | −7 | −7 |
